HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

NEXT STORY
Roche to launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in countries accepting the CE Mark to enable rapid differentiation of viral respiratory infections
PREV STORY
Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Curetis Establishes U.S. Scientific Advisory Board

author_avatar
NASDAQ Market News

Genocea Provides Corporate Update and Reports Third Quarter 2019 Financial Results

author_avatar
NASDAQ Market News

Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas

– AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC – ...

author_avatar
NASDAQ Market News